Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis
Furst, D.E.; Koehnke, R.; Burmeister, L.F.; Kohler, J.; Cargill, I.
Journal of Rheumatology 16(3): 313-320
1989
ISSN/ISBN: 0315-162X PMID: 2724250 Document Number: 687
Forty-six patients with recalcitrant rheumatoid arthritis entered a trial encompassing a 2-week inpatient period plus a 16-week, randomized double blind, parallel study comparing placebo, 5 mg/m2 and 10 mg/m2 oral weekly methotrexate (MTX). An additional 6 patients, given 20 mg/m2 MTX, contributed to the toxicity, but not the efficacy analysis. All patients had "failed" either gold or D-penicillamine. A linear dose response relationship (placebo vs 5 mg/m2 vs 10 mg/m2) was found for 5 of 11 outcome variables: patient pain and patient global scale, physician global scale, joint tenderness count and activity of daily living scale (p less than 0.05 for each). Gastrointestinal toxicity (p = 0.002), dyspepsia (p less than 0.03) and stomatitis (p less than 0.09) occurred more commonly with MTX, and a general trend, although not significant, was found toward a dose toxicity relationship.
Document emailed within 1 workday
